

講師略歴（敬称略） ※随時更新いたします。

Keith Crandell

Keith Crandell is a co-founder and a Managing Director of ARCH Venture Partners. Mr. Crandell focuses on life science therapeutics, tools, devices and diagnostics, specialty materials, electronics, instrumentation, and photonics businesses.

Mr. Crandell has played a key role in the formation and initial funding round of 908 Devices (MASS), Adesto Technologies (IOTS – acquired by Renesas Electronics Corp.), DA32 Life Science Tech Acquisition Corp. (DAL5), Arbor Biotechnologies, ALIS Corp. (acquired by Carl Zeiss SMT), Cytrellis Biosystems, Eichrom Industries (acquired by Gary Comer, Inc.), Illinois Superconductor (ISCO), Nanophase Technologies (NANX), Quanterix (QTRX), Scale Biosciences, Twist Bioscience (TWST), Ultivue and Vizgen.

He was also responsible for ARCH's investment in Ahura Scientific (acquired by Thermo Fisher Scientific-TMO), Apropos Technology (APRS – acquired by Syntellect-ESL), Boreal Genomics, CelebrateExpress (BDAY – acquired by Liberty Media-LINTA), Crystal IS (acquired by Asahi Kasei-AHKS), New Era of Networks (NEON – acquired by Sybase-SY), Teach.com (acquired by Intellinex), among others.

Mr. Crandell is a director of MASS, TWST, Arbor Biotechnologies, Cytrellis Biosystems, Lightcast Discovery, Scale Biosciences, Ultivue, UltraDx, Vizgen and is an observer of AIRNA, Quantum Circuits and Slingshot Biosciences. He previously served as a director of MicroOptical Devices (acquired by EMCORE-EMKR), Nanosys, and was an early director of Engineering Animation (EAI – acquired by Unigraphics).

Mr. Crandell has served on the Entrepreneurship Advisory Board at the Polsky Center for Entrepreneurship, ChicagoBooth since 2005 and the University of Chicago Pritzker School of Molecular Engineering Advisory Council since 2017. Mr. Crandell also serves on the investment advisory board for the Mass General Brigham Innovation Fund, a venture capital fund affiliated with Harvard Medical School Hospitals. He has been active with the Illinois Venture Capital Association since its inception, previously serving as Chairman. He previously served as a Director of the National Venture Capital Association and the Governmental Affairs Committee.

Prior to the founding of ARCH, Mr. Crandell was with the specialty chemical and polymer company, Hercules, Inc.

Mr. Crandell holds an M.B.A. from The University of Chicago, an M.S. in Chemistry from the University of Texas at Arlington, and a B.S. in Chemistry and Mathematics from St. Lawrence University.

Philippe Fauchet, O.B.E.

Philippe began his career in the pharmaceutical industry with Roussel Uclaf and Hoechst Marion Roussel, later joining Sanofi. His expertise, particularly in the Asia Pacific region, was shaped through various roles in Japan and Korea. At Sanofi, he ascended to prominent regional positions, overseeing Eastern & Central Europe, and served as President &

Representative Director of Sanofi-Synthelabo K.K. and Sanofi-Aventis K.K. in Japan. Subsequently, he was appointed Senior Vice President, Corporate Business Development Head of the Sanofi-Aventis Group and was a member of its Management Committee.

His journey continued at GlaxoSmithKline K.K. in Japan, where he served as President & Representative Director, and later as Chairman. Beyond corporate leadership, Philippe has been a Senior Advisor to EFPIA and Chairman of the association. He is also a French Foreign Trade Honorary Advisor (CCE) and a member of the UK-Japan 21st Century Group. As a Global Ambassador of the G20 Health & Development Partnership, he has contributed significantly to global health initiatives, including as an international advisor to the Hiroshima G7 Global Health Task Force. He serves on the boards of biotech companies in Japan and the US and is a venture partner at 4BioCapital, a VC firm based in the UK.

In academia, Philippe has held the position of Adjunct Professor at the University of Tokyo, Graduate School of Medicine, Global Health Policy Department, and is an Affiliate Senior Research Fellow at the Tokyo Foundation for Policy Research.

He is an alumnus of Hautes Études Commerciales (HEC), France, and holds a Bachelor of Law from Paris University. Philippe was honored as an Officer of the Most Excellent Order of the British Empire (O.B.E.) in recognition of his substantial contributions to the field.